FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

<b>STATEMENT</b>	<b>OF CHANGES</b>	IN BENEFICIAL	<b>OWNERSHIP</b>

OMB APPRO	DVAL
OMB Number:	3235-0287
Estimated average burd	len
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*				2. Issuer Name and Ticker or Trading Symbol Unum Therapeutics Inc. [ UMRX ]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
Aldag J	<u>orn</u>					<u> </u>	PCC	treo mier	ominar j			X Directo	r		10% Ow	ner
(Last)	`	irst) APEUTICS INC	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/18/2019							Officer below)	(give title		Other (sp below)	pecify
200 CAMBRIDGE PARK DRIVE, SUITE 3100				4	4. If Amendment, Date of Original Filed (Month/Day/Year)					6. Ir	6. Individual or Joint/Group Filing (Check Applicable					
(Street)	IDGE M	Ά	02140								Line	X Form fi	led by One led by More		Ü	
(City)	(S	tate)	(Zip)													
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date			2. Transactio Date Month/Day/	Execution Date,		Code (Ins				5. Amour Securitie Beneficia Owned F	s ally ollowing	Form:	Direct of Etr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						Code V	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)					
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Yo	n Date, Transaction Code (Instr.		n of Ex		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	y   G	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	· V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$2.7	06/18/2019		A		14,331		(1)	06/18/2029	Common Stock	14,331	\$0.00	14,331		D	

## **Explanation of Responses:**

1. This option shall vest in full on the earlier of (i) June 18, 2020, and (ii) the next annual meeting of the Issuer's stockholders.

## Remarks:

/s/ Amoli Pandya, as Attorney-06/20/2019 in-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.